ALB and cancer: Of note, targeting albumin (201–204) or using albumin-fusion technology is also used in the case of coagulation factor IX for the treatment of hemophilia B (205), as well as for biotherapeutics for the treatment of diabetes (201, 206), cancer (202, 204) or rheumatoid arthritis (207).